A Freeze on Tailored Antiplatelet Therapy?

The article comments on a landmark analysis of the Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and an Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting (ARCTIC) study. Topics discussed include the ex vivo measures of platelet inhibition and the commonly selected strategies after hospital discharge. Also noted are the limitations to ex vivo platelet function test platform.